228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus  by Donovan, Elysia et al.
CARO 2016                                                                                                                                                                  S83 
_________________________________________________________________________________________________________ 
 
Purpose: Recent sequencing efforts have allowed for the 
molecular taxonomy of prostate cancer (TCGA, 2015). In a sub-
set of patients, mutations and copy-number losses in the 
homologous recombination pathway were found. The TONSL-
MMS22L complex has recently been shown to be involved in the 
recovery from replication stress through homologous 
recombination (Duro et al, 2010; O'Donnell et al, 2010). It 
physically associates with BRCA1/2, RAD51, and RPA. Our study 
sought to correlate TONSL complex expression with biochemical 
relapse in prostate cancer patients 
Methods and Materials: Our cohort consists of 250 patients with 
D’Amico-classified intermediate-risk prostate cancer, treated 
with image-guided radiotherapy (IGRT, n = 116) or radical 
prostatectomy (RadP, n = 134). Pre-treatment biopsies were 
analyzed using the Affymetrix Oncoscan array. The Phoenix and 
AUA criteria was used to define biochemical relapse for RadP and 
IGRT patients respectively. mRNA expression data was taken 
from the TCGA Provisional cohort using cBioPortal (Gao et al., 
2013). 
Results: Copy number alterations of TONSL and MMS22L were 
observed in 31% (n = 78) and 20% (n = 51) of our cohort 
respectively. They were predominantly gains in TONSL, but 
losses in MMS22L. TONSL amplification, but not MMS22L, was 
significantly associated with biochemical recurrence (Chi-square 
= 12, p < 0.001). TONSL remained significantly associated on 
multivariate analysis, controlling for tumour stage, Gleason 
score, and PSA (p < 0.005). In the TCGA cohort, over-expression 
of TONSL (p < 0.005) as well as other members of the homologous 
recombination pathway (e.g. RAD51D, BRCA1, XRCC2, POLD1, 
TOP3A, etc.) were associated with disease recurrence (p < 
0.001). 
Conclusions: We identified a novel association of copy-number 
gain and over-expression of TONSL with biochemical recurrence 
following radical prostatectomy or image-guided radiotherapy. 
This points to a potential gene dosage effect and the central role 
of the homologous recombination pathway in prostate cancer 
progression. 
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Purpose: Serous adenocarcinoma is a rare aggressive histologic 
subtype of endometrial cancer with a high rate of recurrence and 
a poor prognosis even at early stages. The optimal approach to 
adjuvant treatment for early stage disease is unknown. Patients 
with endometrium limited disease and a complete 
lymphadenectomy are presumed to be at lower recurrence risk. 
We report on the pathologic and treatment characteristics of 
recurrent cases in a large cohort of serous endometrial cancer 
patients to investigate whether adjuvant therapy can be omitted 
in low-risk cases. 
Methods and Materials: A retrospective chart review inclusive of 
all cases of “serous carcinoma” of the endometrium from 2000-
2014 was completed. Patients with FIGO 2009 Stage IA pure or 
mixed serous histology who had undergone total hysterectomy 
and bilateral salpingo-oophorectomy were included. Kaplan-
Meier estimates were calculated for OS and RFS and hazard ratios 
for prognostic factors were calculated using Cox proportional 
hazards modeling. 
Results: There were 63 patients with FIGO Stage 1A disease. 
Median follow up was 30.2 months. Patients were observed (n = 
33) or received adjuvant treatment (chemotherapy plus 
brachytherapy n = 21; chemotherapy alone n = 7; or pelvic 
radiotherapy +/- chemotherapy n = 2). Fifty-seven patients 
(80.2%) had pelvic lymphadenectomy (median 9 nodes). Thirty-
two patients had endometrium-confined disease. There were 
seven recurrences (11.1%), at a median of 11 months (range 8-
35). At two and five years RFS was 89.3% and 85.8%; and OS was 
92.7% and 87.6%, respectively. Of those patients observed, four 
(12.1%) developed recurrence, with two vaginal recurrences 
only. In patients with endometrium-confined disease 9% 
developed recurrence, none of whom received adjuvant therapy. 
Two of 29 patients treated with chemotherapy as a component 
of their adjuvant treatment developed recurrence (6.9%). The 
majority of patients who recurred had extrapelvic recurrence 
with or without locoregional recurrence (71.4%). More than half 
of patients who recurred did not have adequate pelvic lymph 
node assessment (four of seven cases). On multivariate analysis 
only presence of myometrial invasion (HR 1.41, p = 0.63) and 
presence of lymphovascular invasion (HR 2.69, p = 0.29) were 
associated with inferior RFS, however these were not statistically 
significant. 
Discussion: In our cohort of early stage serous endometrial 
cancers RFS and OS were inferior to those reported for patients 
with endometriod histology. Our study indicates the importance 
of adequate surgical staging in early stage disease and supports 
the use of combination chemotherapy and brachytherapy in 
adjuvant treatment, even in patients with endometrium-
confined Stage 1A disease. 
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Purpose: Surgery and post-operative adjuvant chemotherapy are 
the mainstay of treatment for patients with Stage IIIC2 
endometrial cancer. The benefit of post-operative adjuvant 
radiotherapy (RT) is not as well defined. The purpose of this 
study was to compare the patterns of failure and survival in 
patients with Stage IIIC2 endometrial cancer, treated with or 
without post-operative RT, between two provinces where 
patterns of practice differ. 
Methods and Materials: Consecutive patients diagnosed with 
FIGO Stage IIIC2 endometrial cancer from 2000-2010 were 
identified through two provincial cancer registries. 
Clinicopathologic characteristics, treatment variables (adjuvant 
chemotherapy, radiation therapy), and outcomes (patterns of 
failure, disease-free survival (DFS) and overall survival (OS) were 
analyzed. Statistical analysis was performed on STATA 14. 
Results: Fifty patients with FIGO Stage IIIC2 endometrial cancer 
were identified. Twenty-three (46%) received adjuvant RT and 
27 (54%) did not receive any adjuvant RT (RT versus NRT). Ten 
received external beam RT (EBRT) to pelvic +/- para-aortic 
lymph nodes only; one received vaginal brachytherapy only; 11 
received both (one unknown). The median age at diagnosis was 
55 for the RT group and 69 for NRT group. Grade, histology, and 
depth of myometrial invasion were similar in both groups. The 
RT group received a median of three cycles of adjuvant 
chemotherapy, while the NRT group received six cycles. Twelve 
patients (52%) in the RT group and 21 patients (78%) in the NRT 
group had disease relapse. Distant and abdominal relapse rates 
were lower in the RT versus NRT groups, (30 versus 44%, and 26 
versus 48%, respectively); pelvic/vaginal relapses (17 versus 15%) 
were similar. Median DFS was better in RT group (26.7 versus 
12.5 months, p = 0.013), while median OS was not significantly 
different (32.5 versus 29.7 months, p = 0.26). Toxicities for the 
RT group consisted of Grade 1 and 2 gastrointestinal and 
genitourinary symptoms and fatigue; Grade 3 toxicities were 
uncommon. Further data collection to increase sample size is 
ongoing. 
Conclusions: Patients with Stage IIIC2 endometrial cancer who 
received adjuvant post-operative RT following three cycles of 
